Search the Newsreel

Goosehead Insurance (GSHD) shows 2.5% stake held by T. Rowe Price

T. Rowe Price Investment Management, Inc. has filed an updated ownership report for Goosehead Insurance Inc. (GSHD), indicating beneficial ownership of 602,345 shares, which represents 2.5% of the common stock. The firm holds sole voting power over 600,854 shares and sole dispositive power over …

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants

Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds …

Renaissance Technologies LLC Has $1.20 Million Holdings in Bowhead Specialty Holdings Inc. $BOW

Renaissance Technologies LLC significantly reduced its stake in Bowhead Specialty Holdings Inc. by 77.3% in the first quarter, selling 181,700 shares and retaining 53,400 shares valued at approximately $1.20 million. Despite this, other institutional investors like Dimensional Fund Advisors and First Trust Advisors increased …

Mainland Headwear Sets August Board Meeting to Approve Interim Results and Consider Dividend

GSHD stockholder (NASDAQ: GSHD) files to sell 15,000 Class A shares

A Class A Common stock holder of Goosehead Insurance, Inc. (NASDAQ: GSHD) has filed a Rule 144 notice to sell 15,000 Class A shares. The proposed sale, valued at $983,250, is planned for August 13, 2026, through J.P. Morgan Securities LLC on NASDAQ. These …

Goosehead Insurance (GSHD): Kayne Anderson Rudnick reports 9.2% ownership stake

Kayne Anderson Rudnick Investment Management, LLC has reported a beneficial ownership of 2,168,931 shares of Goosehead Insurance, Inc. common stock, which accounts for 9.2% of the class as of June 30, 2026. The firm holds both sole and shared voting and dispositive powers over …

Wasatch Advisors LP Acquires 78,209 Shares of Bowhead Specialty Holdings Inc. $BOW

Wasatch Advisors LP significantly increased its stake in Bowhead Specialty Holdings Inc. by 28.9% in the second quarter, now owning 348,437 shares valued at $10.43 million. Despite this, analysts maintain a cautious "Hold" rating for Bowhead Specialty, with an average price target of $33. …

Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight

Arrowhead Pharmaceuticals (ARWR) recently reported Q3 2026 results with sales of US$75.25 million and a net loss of US$194.28 million, attracting renewed investor attention. While the stock trades close to a common fair value estimate of $89.08, a discounted cash flow model suggests a …

Dimensional Fund Advisors LP Increases Stock Holdings in Bowhead Specialty Holdings Inc. $BOW

Dimensional Fund Advisors LP significantly increased its stake in Bowhead Specialty Holdings Inc. by 61.3% in the first quarter, now owning 256,645 shares valued at $5.756 million. Other institutional investors also adjusted their positions in BOW, with several firms issuing varied analyst ratings and …

ARWR Rallies 7% This Week As Europe Edges Closer To Redemplo Approval Amid Analyst Optimism

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Bowman Consulting Group Ltd. (Nasdaq – BWMN), Bowhead Specialty Holdings Inc. (NYSE – BOW), Lantheus Holdings Inc. (Nasdaq – LNTH), Safety Insurance Group Inc. (Nasdaq – SAFT)

Brodsky & Smith is notifying investors about ongoing investigations into four companies: Bowman Consulting Group Ltd. (BWMN), Bowhead Specialty Holdings Inc. (BOW), Lantheus Holdings Inc. (LNTH), and Safety Insurance Group Inc. (SAFT). These investigations concern potential breaches of fiduciary duties by the respective company …

Headwater Exploration Inc. (TSE:HWX) Given Consensus Rating of "Moderate Buy" by Brokerages

Goosehead Insurance Inc (GSHD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Assenagon Asset Management S.A. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 243.8% in the second quarter, bringing its total holdings to 201,927 shares valued at $16.5 million. This move is part of a broader trend where institutional investors now own 62.61% …

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Arrowhead Pharmaceuticals (ARWR) reported a significant increase in Q3 2026 sales but also saw its net loss widen considerably. Despite generating over US$400 million in year-to-date sales, rising expenses and reduced collaboration revenue are impacting profitability, making the success of their late-stage programs like …

Bowhead Specialty Holdings (BOW) Looks Fairly Valued After The $34 A Share Deal

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bowhead Specialty Holdings (BOW) has become a focus for investors after American Family Mutual Insurance Company agreed to acquire the remaining 84.8% stake …

Heads UP Ventures Appoints New Company Secretary and Compliance Officer

Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Pacer Advisors Inc. has invested $1.50 million in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by purchasing 23,922 shares in the first quarter. Institutional investors now own 62.61% of the company. Despite reporting a quarterly revenue beat, Arrowhead Pharmaceuticals missed EPS expectations, leading to some reduced future EPS …

FY2026 Earnings Estimate for ARWR Issued By HC Wainwright

Zacks Research Analysts Increase Earnings Estimates for ARWR

Bowhead Specialty Holdings (BOW) Buyout Deal And Earnings Put Fair Value In Focus

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received an average recommendation of "Moderate Buy" from thirteen brokerages, with an average 12-month price target of $97.33. Analysts have mixed outlooks, with some raising price targets and long-term EPS forecasts, while others cut near-term earnings estimates, reflecting expected …

Dimensional Fund Advisors LP Cuts Stock Position in Goosehead Insurance $GSHD

Empowered Funds LLC Acquires Shares of 64,091 Bowhead Specialty Holdings Inc. $BOW

Empowered Funds LLC has acquired a new stake of 64,091 shares in Bowhead Specialty Holdings Inc. (NYSE:BOW), valued at approximately $1.438 million, making them owners of about 0.20% of the company. Other institutional investors have also adjusted their positions in Bowhead Specialty, while analysts …

Goosehead Insurance (GSHD): Durable Capital discloses 10.8% Class A ownership

Durable Capital Partners has filed an amendment (SCHEDULE 13G/A) reporting a 10.8% ownership stake in Goosehead Insurance, Inc.'s Class A common stock, totaling 2,570,260 shares. These shares are directly held by Durable Capital Master Fund LP, with Durable Capital Partners, as the investment adviser, …

Bowhead Specialty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bowhead Specialty Holdings Inc. - BOW

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Bowhead Specialty Holdings Inc. (NYSE: BOW) to American Family Mutual Insurance Company, S.I. Shareholders are set to receive $34.00 per share in cash. KSF is scrutinizing whether this price and the sale …

Company Insider Scoops Up 1,600 Shares of Insurance Stock

A director at Goosehead Insurance, Peter R. Lane, recently purchased 1,600 shares of the company's Class A Common Stock for approximately $101,000. This direct acquisition, made at a premium to the market close price, occurred after the stock experienced a 32% decline over the …

Goosehead Insurance (GSHD) Stock Looks Fully Valued While Earnings Still Look Rich

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress

Arrowhead Pharmaceuticals (ARWR) stock dropped 3% after reporting a widening net loss of US$194.3m in Q3 2026, despite increased revenue and positive Phase III trial results for plozasiran. The market reacted to the deepening losses, while long-term investors are likely weighing the R&D spend …

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside

Arrowhead Pharmaceuticals, Inc. (ARWR) has seen its average 12-month price target raised from $107.6 to $110.2 by 10 analysts, suggesting a 23% potential upside from its August 4th closing price. The consensus rating for the stock remains a "Buy" among 14 covering analysts, with …

Goosehead Insurance (NASDAQ:GSHD) Major Shareholder Sells 22,481 Shares of Stock

Goosehead Insurance (GSHD) holder Durable Capital buys 36,256 shares

Durable Capital Partners LP, a 10% owner of Goosehead Insurance (GSHD), indirectly purchased 36,256 shares of Class A Common Stock on July 31, 2026. The shares were acquired in two separate open-market or private transactions at prices of $61.88 and $62.00 per share. These …